The power of phase II end-points for different possible mechanisms of action of an experimental treatment

BACKGROUND: The high failure rate in phase III oncology trials is partly because the signal obtained from phase II trials is often weak. Several papers have considered the appropriateness of various phase II end-points for individual trials, but there has not been a systematic comparison using simul...

Descripción completa

Detalles Bibliográficos
Autores principales: Wason, J.M.S., Dentamaro, A., Eisen, T.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435668/
https://www.ncbi.nlm.nih.gov/pubmed/25840669
http://dx.doi.org/10.1016/j.ejca.2015.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435668/
https://www.ncbi.nlm.nih.gov/pubmed/25840669
http://dx.doi.org/10.1016/j.ejca.2015.03.002

Ejemplares similares